Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapeutics, has announced its participation in the Stifel 2025 Virtual Targeted Oncology Forum.
The company's presentation is scheduled for Tuesday, April 8, 2025, at 3:00 PM EDT. Investors and interested parties can access the presentation through a webcast link, and a replay will be available on Compass' Events page for 90 days following the event.
Compass Therapeutics (Nasdaq: CMPX), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie anticorpali per il cancro, ha annunciato la sua partecipazione al Stifel 2025 Virtual Targeted Oncology Forum.
La presentazione dell'azienda è programmata per martedì 8 aprile 2025, alle 15:00 EDT. Gli investitori e le parti interessate possono accedere alla presentazione tramite un link per webcast, e una registrazione sarà disponibile sulla pagina Eventi di Compass per 90 giorni dopo l'evento.
Compass Therapeutics (Nasdaq: CMPX), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de terapias anticuerpos para el cáncer, ha anunciado su participación en el Stifel 2025 Virtual Targeted Oncology Forum.
La presentación de la empresa está programada para el martes 8 de abril de 2025 a las 3:00 PM EDT. Los inversores y partes interesadas pueden acceder a la presentación a través de un enlace de webcast, y una repetición estará disponible en la página de Eventos de Compass durante 90 días después del evento.
Compass Therapeutics (Nasdaq: CMPX), 항체 기반 암 치료제를 개발하는 임상 단계의 생명공학 회사가 Stifel 2025 Virtual Targeted Oncology Forum에 참여한다고 발표했습니다.
회사의 발표는 2025년 4월 8일 화요일 오후 3시 EDT로 예정되어 있습니다. 투자자와 관심 있는 분들은 웹캐스트 링크를 통해 발표에 접근할 수 있으며, 이벤트 후 90일 동안 Compass의 이벤트 페이지에서 다시 볼 수 있습니다.
Compass Therapeutics (Nasdaq: CMPX), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies anticorps contre le cancer, a annoncé sa participation au Stifel 2025 Virtual Targeted Oncology Forum.
La présentation de l'entreprise est prévue pour mardi 8 avril 2025 à 15h00 EDT. Les investisseurs et les parties intéressées peuvent accéder à la présentation via un lien de webdiffusion, et un enregistrement sera disponible sur la page Événements de Compass pendant 90 jours après l'événement.
Compass Therapeutics (Nasdaq: CMPX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Antikörper-basierten Krebstherapien konzentriert, hat seine Teilnahme am Stifel 2025 Virtual Targeted Oncology Forum angekündigt.
Die Präsentation des Unternehmens ist für Dienstag, den 8. April 2025, um 15:00 Uhr EDT geplant. Investoren und Interessierte können über einen Webcast-Link auf die Präsentation zugreifen, und eine Wiederholung wird 90 Tage nach der Veranstaltung auf der Veranstaltungsseite von Compass verfügbar sein.
- None.
- None.
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Stifel 2025 Virtual Targeted Oncology Forum taking place April 8-9, 2025.
Presentation Details
Date: Tuesday, April 8, 2025
Time: 3:00 PM EDT
Webcast Link: https://wsw.com/webcast/stifel99/cmpx/2119000
Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ Events page.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099
FAQ
When is Compass Therapeutics (CMPX) presenting at the Stifel 2025 Virtual Oncology Forum?
How long will the CMPX Stifel presentation replay be available?
What type of therapeutics is CMPX developing?
Where can investors watch the CMPX Stifel presentation?
